Anti-Mouse CD120a (TNFR1) (Clone 55R-170) – Purified in vivo GOLD™ Functional Grade

Purified Recombinant Mouse TNFR1 (>98%)

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Clone 55R-170 recognizes mouse CD120a.

Tumor Necrosis Factor Receptor Type I (TNFRI) is a 55kD Type I transmembrane protein. TNFRI is expressed independently of TNFRII at low levels on a wide variety of cell types. TNFRI binds TNF-α and TNF-ß (also known as LT-α). The subsequent signaling is known to be important for inducing cytolytic activity, antiviral activity, expression of manganous superoxide dismutase and intercellular adhesion molecule (ICAM), IL-6 mRNA accumulation and NF-ĸB induction. TNFRI carries an approximately 80 amino acid death domain near its carboxy terminus capable of transmitting an apoptotic signal through its interaction with TRADD (TNF Receptor I associated death domain protein). Binding of 55R-170 antibody to TNFRI has been shown to block in vitro and in vivo receptor signaling initiated by ligand binding.

CD120a is constitutively expressed in most tissues.

TNF-α, LT-α (TNF-β)

Apoptosis, NF-κB activation, inflammation, tumor necrosis, cell differentiation

1. Dana, R. et al. (2000) Arch Ophthalmol. 118: 1666
2. Donner, DB. et al. (2008) J Immunol. 181: 1288
3. Pasparakis, M. et al. (2008) Nat Immunol. 9: 1015